Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ALNY
  • CUSIP: 02043Q10
Key Metrics:
  • Previous Close: $36.68
  • 50 Day Moving Average: $60.584
  • 200 Day Moving Average: $64.228
  • 52-Week Range: $33.16 - $110.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.29
  • P/E Growth: -0.330
  • Market Cap: $3.14B
  • Outstanding Shares: 85,724,000
  • Beta: 2.51
  • Net Margins: -1,204.91%
  • Return on Equity: -29.60%
  • Return on Assets: -26.12%
  • Debt-to-Equity Ratio: 0.14%
  • Current Ratio: 12.58%
  • Quick Ratio: 12.58%
Additional Links:
Companies Related to Alnylam Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) (?)
Ratings Breakdown: 8 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $79.13 (115.77% upside)

Analysts' Ratings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateFirmActionRatingPrice TargetDetails
10/8/2016Cowen and CompanyReiterated RatingOutperform$150.00 -> $100.00View Rating Details
10/6/2016Piper Jaffray Cos.Set Price TargetBuy$106.00View Rating Details
10/7/2016Morgan StanleyDowngradeOverweight -> Equal Weight$38.00 -> $36.00View Rating Details
10/6/2016FBR & CoLower Price TargetOutperform$180.00 -> $100.00View Rating Details
10/6/2016Goldman Sachs Group Inc.Lower Price TargetNeutral$65.00 -> $34.00View Rating Details
10/6/2016Stifel NicolausLower Price TargetHold$68.00 -> $36.00View Rating Details
10/6/2016Jefferies GroupLower Price TargetBuy$86.00 -> $58.00View Rating Details
10/6/2016Needham & Company LLCDowngradeBuy$152.00 -> $137.00View Rating Details
10/6/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$83.00 -> $51.00View Rating Details
10/6/2016Leerink SwannDowngradeOutperform -> Market Perform$107.00 -> $40.00View Rating Details
10/6/2016Barclays PLCDowngradeOverweight -> Equal Weight$85.00 -> $50.00View Rating Details
9/30/2016Credit Suisse Group AGSet Price TargetBuy$145.00View Rating Details
9/28/2016Janney Montgomery ScottInitiated CoverageNeutral$74.00View Rating Details
7/11/2016Chardan CapitalReiterated RatingBuyView Rating Details
7/10/2016JMP SecuritiesReiterated RatingBuyView Rating Details
11/26/2015S&P Equity ResearchDowngradeBuy -> HoldView Rating Details
6/24/2015Deutsche Bank AGSet Price TargetBuy$155.00View Rating Details
6/24/2015Canaccord GenuityReiterated RatingBuy$160.00View Rating Details
(Data available from 10/21/2014 forward)


Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($1.24)($1.05)$8.09 million$8.70 millionViewListenView Earnings Details
5/2/2016Q116($1.05)($1.21)$7.79 million$7.30 millionViewListenView Earnings Details
2/11/2016Q415($0.96)($1.07)$9.59 million$7.60 millionViewListenView Earnings Details
11/9/2015Q315($0.91)($0.91)$7.55 million$6.30 millionViewN/AView Earnings Details
8/6/2015Q215($0.75)($0.85)$12.64 million$8.69 millionViewN/AView Earnings Details
5/7/2015Q115($0.66)($0.62)$15.40 million$18.51 millionViewN/AView Earnings Details
2/12/2015Q414($0.60)($0.28)$13.10 million$24.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.63)($0.58)$8.93 million$11.00 millionViewN/AView Earnings Details
8/7/2014Q214($0.56)($0.63)$9.36 million$7.30 millionViewN/AView Earnings Details
5/8/2014Q114($0.54)($0.39)$10.80 million$8.30 millionViewN/AView Earnings Details
2/19/2014Q413($0.45)($0.51)$9.98 million$10.80 millionViewN/AView Earnings Details
11/6/2013Q313($0.39)($0.48)$8.64 million$9.00 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.35)($0.29)$8.99 million$8.70 millionViewListenView Earnings Details
5/6/2013Q1 2013($0.29)($0.15)$15.56 million$18.60 millionViewListenView Earnings Details
2/7/2013Q4 2012($1.45)($1.20)$15.82 million$8.50 millionViewListenView Earnings Details
11/5/2012Q312($0.32)($0.31)$17.30 million$16.80 millionViewN/AView Earnings Details
8/6/2012($0.21)($0.25)ViewN/AView Earnings Details
5/3/2012($0.35)($0.25)ViewN/AView Earnings Details
2/9/2012($0.33)($0.33)ViewN/AView Earnings Details
11/1/2011($0.35)($0.31)ViewN/AView Earnings Details
8/1/2011($0.36)($0.33)ViewN/AView Earnings Details
5/2/2011($0.30)($0.38)ViewN/AView Earnings Details
2/17/2011($0.35)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Current Year EPS Consensus Estimate: $-4.680 EPS
Next Year EPS Consensus Estimate: $-5.030 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.14)($1.08)($1.11)
Q2 20164($1.32)($1.19)($1.26)
Q3 20164($1.35)($1.25)($1.30)
Q4 20164($1.41)($0.48)($1.14)
(Data provided by Zacks Investment Research)


Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 85.95%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/13/2016David E I PyottDirectorBuy27,900$37.00$1,032,300.00View SEC Filing  
7/20/2016John MaraganoreCEOSell30,151$64.69$1,950,468.19View SEC Filing  
4/20/2016John MaraganoreCEOSell30,151$67.46$2,033,986.46View SEC Filing  
3/9/2016Michael W BonneyDirectorBuy2,000$58.36$116,720.00View SEC Filing  
2/22/2016David-Alexandre C GrosSVPBuy1,000$62.75$62,750.00View SEC Filing  
2/1/2016SanofiMajor ShareholderBuy205,030$69.75$14,300,842.50View SEC Filing  
1/20/2016John MaraganoreCEOSell30,152$71.78$2,164,310.56View SEC Filing  
12/4/2015Philip A. SharpDirectorSell30,000$109.00$3,270,000.00View SEC Filing  
12/2/2015John MaraganoreCEOSell58,689$104.87$6,154,715.43View SEC Filing  
11/20/2015John MaraganoreCEOSell58,690$102.88$6,038,027.20View SEC Filing  
11/12/2015Kevin P. StarrDirectorSell75,000$103.89$7,791,750.00View SEC Filing  
6/16/2015Akshay VaishnawCMOSell8,750$128.83$1,127,262.50View SEC Filing  
5/12/2015Michael W BonneyDirectorBuy2,000$112.16$224,320.00View SEC Filing  
4/21/2015Paul SchimmelDirectorSell10,000$130.02$1,300,200.00View SEC Filing  
3/19/2015Dennis A AusielloDirectorSell5,000$120.00$600,000.00View SEC Filing  
3/17/2015Akshay VaishnawCMOSell8,750$116.86$1,022,525.00View SEC Filing  
1/29/2015SanofiMajor ShareholderBuy97,118$95.00$9,226,210.00View SEC Filing  
1/26/2015John MaraganoreCEOBuy10,000$95.00$950,000.00View SEC Filing  
1/26/2015Steven M PaulDirectorBuy1,000$95.00$95,000.00View SEC Filing  
12/19/2014Barry E GreeneCOOSell11,200$100.00$1,120,000.00View SEC Filing  
12/16/2014Akshay VaishnawEVPSell10,626$93.60$994,593.60View SEC Filing  
12/15/2014Michael MasonVPSell22,162$97.50$2,160,795.00View SEC Filing  
11/18/2014Laurence ReidSVPSell10,000$90.67$906,700.00View SEC Filing  
11/17/2014Barry E GreeneCOOSell33,200$89.63$2,975,716.00View SEC Filing  
10/28/2014Paul SchimmelDirectorSell15,000$95.00$1,425,000.00View SEC Filing  
10/22/2014Dennis A AusielloDirectorSell5,000$90.00$450,000.00View SEC Filing  
10/13/2014Philip A SharpDirectorSell110,000$85.00$9,350,000.00View SEC Filing  
9/25/2014Kevin P StarrDirectorSell90,000$78.09$7,028,100.00View SEC Filing  
9/24/2014Kevin P StarrDirectorSell45,000$79.08$3,558,600.00View SEC Filing  
9/18/2014John MaraganoreCEOSell113,668$77.71$8,833,140.28View SEC Filing  
9/16/2014Akshay VaishnawEVPSell10,625$72.04$765,425.00View SEC Filing  
8/18/2014Laurence ReidSVPSell13,500$67.34$909,090.00View SEC Filing  
6/26/2014John MaraganoreCEOSell113,668$65.45$7,439,570.60View SEC Filing  
6/17/2014Akshay VaishnawEVPSell10,625$69.82$741,837.50View SEC Filing  
5/21/2014John ClarkeDirectorSell35,000$53.80$1,883,000.00View SEC Filing  
5/19/2014Laurence ReidSVPSell13,500$57.83$780,705.00View SEC Filing  
5/15/2014John MaraganoreCEOSell113,668$56.73$6,448,385.64View SEC Filing  
3/25/2014Sanofimajor shareholderBuy344,448$66.88$23,036,682.24View SEC Filing  
3/18/2014Akshay VaishnawEVPSell32,769$73.95$2,423,267.55View SEC Filing  
2/19/2014Laurence ReidSVPSell20,400$80.06$1,633,224.00View SEC Filing  
1/24/2014Akshay VaishnawEVPSell7,890$85.75$676,567.50View SEC Filing  
1/13/2014Paul SchimmelDirectorSell15,000$85.36$1,280,400.00View SEC Filing  
12/20/2013Paul SchimmelDirectorSell15,000$65.00$975,000.00View SEC Filing  
12/17/2013Akshay VaishnawEVPSell33,480$60.72$2,032,905.60View SEC Filing  
10/22/2013Paul SchimmelDirectorSell15,000$60.00$900,000.00View SEC Filing  
9/11/2013John MaraganoreCEOSell58,947$55.50$3,271,558.50View SEC Filing  
9/10/2013Akshay VaishnawEVPSell6,250$57.48$359,250.00View SEC Filing  
8/14/2013John MaraganoreCEOSell60,000$48.97$2,938,200.00View SEC Filing  
7/12/2013Michael MasonVPSell14,200$50.00$710,000.00View SEC Filing  
7/10/2013John MaraganoreCEOSell60,000$37.11$2,226,600.00View SEC Filing  
7/1/2013Michael MasonVPSell27,000$32.00$864,000.00View SEC Filing  
6/17/2013Michael MasonVPSell23,625$29.93$707,096.25View SEC Filing  
6/11/2013Akshay VaishnawEVPSell15,000$31.08$466,200.00View SEC Filing  
5/28/2013Barry E GreeneCOOSell22,822$30.00$684,660.00View SEC Filing  
5/28/2013Laurence ReidSVPSell5,000$30.00$150,000.00View SEC Filing  
3/26/2013Kevin P StarrDirectorSell52,631$23.49$1,236,302.19View SEC Filing  
1/22/2013Philip A SharpDirectorBuy4,967$20.13$99,985.71View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Alnylam Pharmaceuticals (NASDAQ:ALNY)
News IconBiotech Companies To Look Out For: Geron Corporation (GERN ... - The Independent Republic (NASDAQ:ALNY) - October 21 at 8:28 PM
News IconBiotech news that matter for investors: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Novavax, Inc. (NASDAQ:NVAX) - The Voice Registrar (NASDAQ:ALNY) - October 21 at 8:28 PM
News IconScorching Hot Biotech Stocks Tape: ImmunoGen (IMGN), Alnylam Pharmaceuticals (ALNY) - The Independent Republic (NASDAQ:ALNY) - October 20 at 9:20 PM
News IconBiotech Stocks To Put On Your Watch List: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Sangamo Biosciences Inc ... - The Voice Registrar (NASDAQ:ALNY) - October 20 at 9:20 PM
News IconAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Assigned A Consensus Outperform Rating - The Independent Republic (NASDAQ:ALNY) - October 20 at 9:20 PM
News IconInvestor News: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) under Investigation over possible Violations of Securities Laws (NASDAQ:ALNY) - October 19 at 8:15 AM
News Icon2 Stocks Analyst-Opinion Need Close Attention Tempur Sealy International Inc (NYSE:TPX), Alnylam Pharmaceuticals ... - The Voice Registrar (NASDAQ:ALNY) - October 18 at 3:25 PM logoAlnylam Pharmaceuticals Has Returned 46.8% Since SmarTrend Recommendation (ALNY) (NASDAQ:ALNY) - October 18 at 8:13 AM
News IconShare Value Diminishing Over Past Month: Alnylam ... - CSZ News - CSZ News (NASDAQ:ALNY) - October 17 at 8:15 AM
News IconLooking Ahead for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY); Are These Shares Ready to Go Higher? - CSZ News (NASDAQ:ALNY) - October 17 at 8:15 AM logoWeekly Top Insider Buys Highlight for Week of Oct. 14 (NASDAQ:ALNY) - October 17 at 8:15 AM
News IconShare Value Diminishing Over Past Month: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - CSZ News (NASDAQ:ALNY) - October 16 at 8:13 AM
News IconUpdate on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for the day (NASDAQ:ALNY) - October 15 at 3:23 PM
News IconInsider Activity to Watch: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - The Voice Registrar (NASDAQ:ALNY) - October 15 at 8:13 AM
News IconIntraday Active Biotech Stocks News: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Sarepta Therapeutics, Inc ... - The Voice Registrar (NASDAQ:ALNY) - October 14 at 3:24 PM
News IconAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Analysts Recommendations and Insider Trading - The Independent Republic (NASDAQ:ALNY) - October 14 at 3:24 PM
News IconBiotech Stocks Worth Chasing: Alnylam Pharmaceuticals, Inc. (ALNY) - The Independent Republic (NASDAQ:ALNY) - October 13 at 3:25 PM
News Icon2 Stocks Analyst-Opinion Need Close Attention Aecom (NYSE:ACM), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - The Voice Registrar (NASDAQ:ALNY) - October 13 at 3:25 PM
News IconIntraday Active Biotech Stocks News: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR), Alnylam Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:ALNY) - October 13 at 3:25 PM
News Icon2 Stocks Attracting Analyst Attention: PulteGroup, Inc. (NYSE:PHM ... - The Voice Registrar (NASDAQ:ALNY) - October 12 at 6:58 AM
News IconInsiders are Curtailing Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - CSZ News (NASDAQ:ALNY) - October 12 at 6:58 AM
News IconBetter Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc. - Fox Business (NASDAQ:ALNY) - October 12 at 6:58 AM logoAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is Expected To Post ... - (NASDAQ:ALNY) - October 11 at 8:30 PM
News IconTop Biotechnology Stock Picking: Alnylam Pharmaceuticals, Inc ... - The Independent Republic (NASDAQ:ALNY) - October 11 at 8:30 PM logoAlnylam Says Trial of Patisiran Can Continue Following Revusiran Halt (NASDAQ:ALNY) - October 11 at 3:28 PM logoInvestigation for Investors in Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Announced (NASDAQ:ALNY) - October 11 at 3:28 PM
News IconSimplex Trading Lowers stake in Alnylam Pharmaceuticals (ALNY) (NASDAQ:ALNY) - October 11 at 3:28 PM logoAlnylam Pharma (ALNY) Says DMC Recommends Continuation of ... - (NASDAQ:ALNY) - October 10 at 3:23 PM logoBetter Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics ... - Motley Fool (NASDAQ:ALNY) - October 10 at 3:23 PM logoAlnylam Pharmaceuticals (ALNY) Stock Gains on Late-Stage Trial Continuation (NASDAQ:ALNY) - October 10 at 3:23 PM
News IconTop Biotechnology Stock Picking: Alnylam Pharmaceuticals, Inc. (ALNY), Merrimack Pharmaceuticals, Inc. (MACK) - The Independent Republic (NASDAQ:ALNY) - October 10 at 8:12 AM logoData Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN) (NASDAQ:ALNY) - October 10 at 8:12 AM logoINVESTOR ALERT: Goldberg Law PC Announces an Investigation of Alnylam Pharmaceuticals, Inc. and Advises ... - Business Wire (press release) (NASDAQ:ALNY) - October 7 at 3:25 PM logoWhat's Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure? - Motley Fool (NASDAQ:ALNY) - October 7 at 3:25 PM
News IconHere’s What Happened With Alnylam Pharmaceuticals, Inc. (ALNY) and Tenax Therapeutics Inc (TENX) (NASDAQ:ALNY) - October 7 at 3:16 PM logoWhat's Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure? (NASDAQ:ALNY) - October 7 at 10:52 AM logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals ... - PR Newswire (press release) (NASDAQ:ALNY) - October 7 at 8:15 AM logoAnalyst Downgrades: Tesla Motors Inc, Smith & Wesson Holding ... - Schaeffers Research (blog) (NASDAQ:ALNY) - October 6 at 3:23 PM logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals ... - PR Newswire (press release) (NASDAQ:ALNY) - October 6 at 3:23 PM logo8 Biggest Price Target Changes For Thursday - Benzinga (NASDAQ:ALNY) - October 6 at 3:23 PM logoAlnylam Pharma stock plummets 45% after discontinuing drug on patient safety concerns - MarketWatch (NASDAQ:ALNY) - October 6 at 3:23 PM logoWhy Alnylam Pharmaceuticals Is Getting Crushed Today - Motley Fool (NASDAQ:ALNY) - October 6 at 3:23 PM logoBiotech's bad year (NASDAQ:ALNY) - October 6 at 3:23 PM logoHere's a Reason Why Ionis Pharmaceuticals (IONS) Stock Is Slumping Today (NASDAQ:ALNY) - October 6 at 3:23 PM logoAlnylam Pharma Discontinues Revusiran Development (NASDAQ:ALNY) - October 6 at 9:11 AM logoBRIEF-Alnylam Pharma says discontinues revusiran development (NASDAQ:ALNY) - October 6 at 9:11 AM logoAlnylam (ALNY) Discontinues Phase III Study on Revusiran (NASDAQ:ALNY) - October 6 at 9:11 AM logoAlnylam Plunges 43% After Ending Development of a Lead Drug (2) (NASDAQ:ALNY) - October 6 at 9:10 AM logoAlnylam shares plunge on abandoned study (NASDAQ:ALNY) - October 6 at 9:10 AM logoStock Futures Edge Lower as Jobless Claims Fall (NASDAQ:ALNY) - October 6 at 9:10 AM


Alnylam Pharmaceuticals (NASDAQ:ALNY) Chart for Friday, October, 21, 2016

Last Updated on 10/21/2016 by Staff